2.445

1.01% -0.025

Geovax Labs Inc (GOVX)

Overview News Price History Financials Discussions Forecast Stock Split

Geovax Labs Inc stock is traded at $2.445, with a volume of 397.97K. It is down -1.01% in the last 24 hours and down -3.36% over the past month. Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Previous Close:

$2.47

Open:

$2.54

24h Volume:

397.97K

Relative Volume:

0.25

Market Cap:

$23.11M

Revenue:

$356.60K

Net Income/Loss:

$-25.97M

P/E Ratio:

-3.2845

EPS:

-0.7444

Net Cash Flow:

$-25.22M

1W Performance:

+4.04%

1M Performance:

-3.36%

6M Performance:

-26.13%

1Y Performance:

-55.95%

1-Day Range:

$2.385

$2.5999

1-Week Range:

$2.27

$2.75

52-Week Range:

$1.0901

$11.18

Geovax Labs Inc Stock (GOVX) Company Profile

Name

Geovax Labs Inc

Sector

Healthcare (1195)

Industry

Biotechnology (670)

Phone

678-384-7220

Address

1900 LAKE PARK DRIVE, SMYRNA

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

GOVX's Discussions on Twitter

Compare GOVX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOVX Geovax Labs Inc	2.445	23.11M	356.60K	-25.97M	-25.22M	-14.29
VRTX Vertex Pharmaceuticals Inc	404.05	103.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	713.57	78.27B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	618.13	36.77B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	233.21	29.99B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	115.16	27.55B	3.30B	-501.07M	1.03B	-2.1146

Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Initiated	Alliance Global Partners	Buy
Jul-16-24	Initiated	ROTH MKM	Buy
Nov-19-20	Initiated	Maxim Group	Buy

Geovax Labs Inc Stock (GOVX) Latest News

01:32 AM

Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World

01:32 AM

Dec 31, 2024

GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Dec 31, 2024

Dec 18, 2024

GeoVax adjourns Special Meeting due to low quorum - Investing.com

Dec 18, 2024

GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia

Dec 18, 2024

Dec 09, 2024

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times

Dec 09, 2024

GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan

Dec 09, 2024

Dec 08, 2024

GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN

Dec 08, 2024

Dec 06, 2024

GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Dec 06, 2024

Dec 02, 2024

Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com

Dec 02, 2024

Nov 30, 2024

Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com

Nov 30, 2024

Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN

Nov 30, 2024

Nov 29, 2024

3 Penny Stocks Ready to Break Out in 2025 - sharewise

Nov 29, 2024

Nov 27, 2024

Geovax Labs (STU:E8LA) Momentum Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com

Nov 27, 2024

Nov 26, 2024

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire

Nov 26, 2024

GeoVax CEO to Present COVID-19 Vaccine & Cancer Therapy Updates at NobleCon20 | GOVX Stock News - StockTitan

Nov 26, 2024

Nov 23, 2024

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN

Nov 23, 2024

Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial - Defense World

Nov 23, 2024

Nov 20, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire

Nov 20, 2024

Nov 19, 2024

GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia

Nov 19, 2024

GeoVax regains compliance with Nasdaq listing standards - Investing.com India

Nov 19, 2024

GeoVax reports progress in CLL vaccine booster trial - Investing.com India

Nov 19, 2024

GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada

Nov 19, 2024

GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks

Nov 19, 2024

GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan

Nov 19, 2024

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - Yahoo Finance

Nov 19, 2024

Nov 16, 2024

Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World

Nov 16, 2024

Nov 15, 2024

Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia

Nov 15, 2024

Earnings call: GeoVax reports progress in vaccine trials, financial updates - Investing.com

Nov 13, 2024

U.S. Stock market top losers: Gaucho Group Holdings sees decline of 55.06% while GeoVax Labs looses 23.53% in early trading - Business Upturn

Nov 13, 2024